| Identification | Back Directory | [Name]
NDI-091143 | [CAS]
2375840-87-0 | [Synonyms]
NDI-091143
NDI-091143;NDI091143;NDI 091143
Benzoic acid, 3-chloro-5-[[(4,6-difluoro[1,1'-biphenyl]-3-yl)amino]sulfonyl]-4-hydroxy-, methyl ester | [Molecular Formula]
C20H14ClF2NO5S | [MDL Number]
MFCD32644582 | [MOL File]
2375840-87-0.mol | [Molecular Weight]
453.84 |
| Hazard Information | Back Directory | [Uses]
NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay), a Ki of 7.0 nM and a Kd of 2.2 nM. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate[1]. | [Biological Activity]
NDI-091143 is a highly potentallosteric ATP-citrate lyase inhibitor (human ACLY IC50 = 4.8 nM by coupled enzyme assay with 85 μM citrate; IC50 = 2.1 nM by ADP-Glo assay) th at indirectly disrupts citrate binding (Ki = 7 nM) by targeting an adjacent hydrophobic site (kon = 1.02 x 10^6/M/skoff = 0.0019/s). | [References]
[1] Wei J, et al. An allosteric mechanism for potent inhibition of human ATP-citrate lyase. Nature. 2019 Apr;568(7753):566-570. DOI:10.1038/s41586-019-1094-6 |
|
|